Synergistic anti-cd47 therapy for hematologic cancers

Abstract

Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.

1 . A method for depleting hematologic cancer cells in a patient, the method comprising:
 administering to said patient at a dose that achieves depletion of hematologic cancer cells, a synergistic combination of agents comprising an agent that prevents interaction between CD47 and SIRPα, and a second agent that selectively binds CD20.   
     
     
         2 . The method of  claim 1 , wherein the first agent is an antibody. 
     
     
         3 - 7 . (canceled) 
     
     
         8 . The method of  claim 1 , wherein the hematologic cancer is non-Hodgkin's lymphoma (NHL). 
     
     
         9 . The method of  claim 8 , wherein the NHL is a diffuse large B cell lymphoma. 
     
     
         10 - 16 . (canceled)